Cargando…

Effect of granulocyte colony-stimulating factor in experimental methicillin resistant Staphylococcus aureus sepsis

BACKGROUND: Methicillin resistant Staphylococcus aureus (MRSA) is the leading pathogenic cause of nosocomial infections, especially in bacteraemia and sepsis. The essential therapy for MRSA infection is glycopeptides. Therapeutic failure can be seen with this therapy and the mortality is still high....

Descripción completa

Detalles Bibliográficos
Autores principales: Alp, Emine, Gozukucuk, Suveyda, Canoz, Ozlem, Kirmaci, Beyhan, Doganay, Mehmet
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2004
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC526191/
https://www.ncbi.nlm.nih.gov/pubmed/15491501
http://dx.doi.org/10.1186/1471-2334-4-43
_version_ 1782121924088823808
author Alp, Emine
Gozukucuk, Suveyda
Canoz, Ozlem
Kirmaci, Beyhan
Doganay, Mehmet
author_facet Alp, Emine
Gozukucuk, Suveyda
Canoz, Ozlem
Kirmaci, Beyhan
Doganay, Mehmet
author_sort Alp, Emine
collection PubMed
description BACKGROUND: Methicillin resistant Staphylococcus aureus (MRSA) is the leading pathogenic cause of nosocomial infections, especially in bacteraemia and sepsis. The essential therapy for MRSA infection is glycopeptides. Therapeutic failure can be seen with this therapy and the mortality is still high. The aim of this study was to evaluate the additional effect of G-CSF on the traditional antibiotic treatment in an experimental MRSA sepsis. METHODS: Experimental sepsis was performed in mice by intraperitoneal injection of MRSA isolate. Inoculum dose was estimated as 6 × 10(9)/ml. Mice were randomised for the study into four group; control group (not receive any therapy), G-CSF group (1000 ng/daily, subcutaneously for 3 d), antibiotic group (vancomycin 25 or 50 mg/kg intraperitoneally every 12 hours for 7 d), and vancomycin+G-CSF group (at the same concentrations and duration). Autopsy was done within one hour after mice died. If mice was still alive at the end of seventh day, they were sacrificed, and autopsy was done. In all groups, the effect of G-CSF therapy on the survival, the number of the MRSA colonies in the lung, liver, heart, spleen, and peritoneal cultures, the histopathology of the lung, liver, heart and spleen was investigated. RESULTS: One hundred and six mice were used. There were no significant differences in survival rates and bacterial eradication in G-CSF group compared with control group, and also in antibiotic +G-CSF group compared with antibiotic alone group. These parameters were all significantly different in antibiotic alone group compared with control group. Histopathologically, inflammation of the lung and liver were significantly reduced in vancomycin (25 mg/kg)+G-CSF and vancomycin (50 mg/kg)+G-CSF subgroups, respectively (p < 0.01). The histopathological inflammation of the other organs was not significantly different in antibiotic+G-CSF group compared with antibiotic group and, also G-CSF group compared with control group. CONCLUSION: G-CSF treatment had no additional effect on survival and bacterial eradication in MRSA sepsis in nonneutropenic mice; and only a little effect on histopathology. G-CSF treatment is very expensive, likewise glycopeptides. The more interest in infection control measures, and prevent the spread of MRSA infections is more rational.
format Text
id pubmed-526191
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-5261912004-11-10 Effect of granulocyte colony-stimulating factor in experimental methicillin resistant Staphylococcus aureus sepsis Alp, Emine Gozukucuk, Suveyda Canoz, Ozlem Kirmaci, Beyhan Doganay, Mehmet BMC Infect Dis Research Article BACKGROUND: Methicillin resistant Staphylococcus aureus (MRSA) is the leading pathogenic cause of nosocomial infections, especially in bacteraemia and sepsis. The essential therapy for MRSA infection is glycopeptides. Therapeutic failure can be seen with this therapy and the mortality is still high. The aim of this study was to evaluate the additional effect of G-CSF on the traditional antibiotic treatment in an experimental MRSA sepsis. METHODS: Experimental sepsis was performed in mice by intraperitoneal injection of MRSA isolate. Inoculum dose was estimated as 6 × 10(9)/ml. Mice were randomised for the study into four group; control group (not receive any therapy), G-CSF group (1000 ng/daily, subcutaneously for 3 d), antibiotic group (vancomycin 25 or 50 mg/kg intraperitoneally every 12 hours for 7 d), and vancomycin+G-CSF group (at the same concentrations and duration). Autopsy was done within one hour after mice died. If mice was still alive at the end of seventh day, they were sacrificed, and autopsy was done. In all groups, the effect of G-CSF therapy on the survival, the number of the MRSA colonies in the lung, liver, heart, spleen, and peritoneal cultures, the histopathology of the lung, liver, heart and spleen was investigated. RESULTS: One hundred and six mice were used. There were no significant differences in survival rates and bacterial eradication in G-CSF group compared with control group, and also in antibiotic +G-CSF group compared with antibiotic alone group. These parameters were all significantly different in antibiotic alone group compared with control group. Histopathologically, inflammation of the lung and liver were significantly reduced in vancomycin (25 mg/kg)+G-CSF and vancomycin (50 mg/kg)+G-CSF subgroups, respectively (p < 0.01). The histopathological inflammation of the other organs was not significantly different in antibiotic+G-CSF group compared with antibiotic group and, also G-CSF group compared with control group. CONCLUSION: G-CSF treatment had no additional effect on survival and bacterial eradication in MRSA sepsis in nonneutropenic mice; and only a little effect on histopathology. G-CSF treatment is very expensive, likewise glycopeptides. The more interest in infection control measures, and prevent the spread of MRSA infections is more rational. BioMed Central 2004-10-18 /pmc/articles/PMC526191/ /pubmed/15491501 http://dx.doi.org/10.1186/1471-2334-4-43 Text en Copyright © 2004 Alp et al; licensee BioMed Central Ltd.
spellingShingle Research Article
Alp, Emine
Gozukucuk, Suveyda
Canoz, Ozlem
Kirmaci, Beyhan
Doganay, Mehmet
Effect of granulocyte colony-stimulating factor in experimental methicillin resistant Staphylococcus aureus sepsis
title Effect of granulocyte colony-stimulating factor in experimental methicillin resistant Staphylococcus aureus sepsis
title_full Effect of granulocyte colony-stimulating factor in experimental methicillin resistant Staphylococcus aureus sepsis
title_fullStr Effect of granulocyte colony-stimulating factor in experimental methicillin resistant Staphylococcus aureus sepsis
title_full_unstemmed Effect of granulocyte colony-stimulating factor in experimental methicillin resistant Staphylococcus aureus sepsis
title_short Effect of granulocyte colony-stimulating factor in experimental methicillin resistant Staphylococcus aureus sepsis
title_sort effect of granulocyte colony-stimulating factor in experimental methicillin resistant staphylococcus aureus sepsis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC526191/
https://www.ncbi.nlm.nih.gov/pubmed/15491501
http://dx.doi.org/10.1186/1471-2334-4-43
work_keys_str_mv AT alpemine effectofgranulocytecolonystimulatingfactorinexperimentalmethicillinresistantstaphylococcusaureussepsis
AT gozukucuksuveyda effectofgranulocytecolonystimulatingfactorinexperimentalmethicillinresistantstaphylococcusaureussepsis
AT canozozlem effectofgranulocytecolonystimulatingfactorinexperimentalmethicillinresistantstaphylococcusaureussepsis
AT kirmacibeyhan effectofgranulocytecolonystimulatingfactorinexperimentalmethicillinresistantstaphylococcusaureussepsis
AT doganaymehmet effectofgranulocytecolonystimulatingfactorinexperimentalmethicillinresistantstaphylococcusaureussepsis